The contribution of <scp>VEGF</scp> signalling to fostamatinib‐induced blood pressure elevation

Abstract

Increased vascular resistance, secondary to reduced VEGF-induced NO release from endothelium, may contribute to BP increases observed with fostamatanib. This is consistent with the elevated BP induced by other drugs inhibiting VEGF signalling, although the contribution of other mechanisms cannot be excluded.